Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Nov 17, 3:30PM CST

WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 17.95 (+5.77%)
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire - Thu Nov 6, 6:00AM CST

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership...

AVTX : 17.95 (+5.77%)
Avalo Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 6:00AM CST

WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 17.95 (+5.77%)
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa GlobeNewswire - Wed Oct 29, 6:00AM CDT

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 17.95 (+5.77%)
Doctor holding money by IherPhoto via iStock
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed Barchart - Sat Oct 11, 11:00AM CDT

While the risks remain significant with biotech stocks, the potential rewards could be equally compelling.

ATXS : 13.12 (+0.23%)
AVTX : 17.95 (+5.77%)
GOSS : 3.32 (-2.92%)
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation Tipranks - Sat Oct 11, 6:42AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Avalo Therapeutics...

AVTX : 17.95 (+5.77%)
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources GlobeNewswire - Wed Oct 1, 6:00AM CDT

WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 17.95 (+5.77%)
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors GlobeNewswire - Mon Sep 22, 6:00AM CDT

WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 17.95 (+5.77%)
Avalo Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Aug 27, 6:00AM CDT

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 17.95 (+5.77%)
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire - Thu Aug 7, 6:00AM CDT

Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026 Rita Jain, M.D. appointed to Board of Directors Cash and short-term investments of...

AVTX : 17.95 (+5.77%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot